{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-044036","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2023-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.212766+00:00","generated_at":"2026-06-11T04:54:28.866379+00:00","sec_items":["2.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pyxis Oncology completes all-stock acquisition of Apexigen for ~$10.7M","bullets":["Pyxis issued ~4.3M shares (exchange ratio 0.1725) so Apexigen holders own ~10% of combined co.","Acquisition adds clinically validated APXiMAB antibody-discovery platform and Phase 2 CD40 agonist sotigalimab (now PYX-107).","Combined co. positions for next-gen ADC creation; cash runway extended into 1H 2025.","Jakob Dupont, former Apexigen director, appointed to Pyxis board as independent Class III director.","Development strategy and timelines for PYX-107 to be shared in 4Q23."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-044036","json":"https://secwatch.observer/filing/0000950170-23-044036.json","markdown":"https://secwatch.observer/filing/0000950170-23-044036.md","text":"https://secwatch.observer/filing/0000950170-23-044036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023044036/0000950170-23-044036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023044036/pyxs-20230823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T04:54:28.866379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"998cddf8a2","claim":"Jakob Dupont was appointed as Director at Pyxis Oncology, Inc..","evidence_excerpt":"On August 23, 2023, effective as of the Effective Time, Jakob Dupont, M.D., a former director of Apexigen, was appointed to the Board as a Class III director and his term will expire at the annual meeting of stockholders to be held in 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023044036/0000950170-23-044036-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e0bc7e830725aa50754eb44db35a08ed0ba8d88a","claim":"Pyxis Oncology, Inc. completed an acquisition involving Apexigen, Inc. for all-stock transaction valued at approximately $10.7 million (closed 2023-08-23).","evidence_excerpt":"clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, in an all-stock transaction valued at approximately $10.7 million. The combined company is positioned at the forefront of ADC innovation with a platform that now includes four key components: novel humanized antibody generation capabilities, an","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023044036/0000950170-23-044036-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Apexigen, Inc."},{"label":"Consideration","value":"all-stock transaction valued at approximately $10.7 million"},{"label":"Closing","value":"2023-08-23"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}